Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

COMMD3:BMI1 Fusion and COMMD3 Protein Regulate C-MYC Transcription: Novel Therapeutic Target for Metastatic Prostate Cancer

29 Aug 2019

Abstract excerpt

Abstract Gene rearrangement is reported to be associated to the aggressive phenotype and poor prognosis in prostate cancer. We identified a gene fusion between a transcription repressor (BMI1) and transcriptional factor (COMMD3) in human prostate cancer. We show that COMMD3:BMI1 fusion expression is significantly increased in prostate cancer disease in an order: normal tissue < primary < metastatic tumors (Mets)....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Prostate Cancer Treatment and Research
Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31467179
DOI: 10.1158/1535-7163.mct-19-0150

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

COMMD3:BMI1 Fusion and COMMD3 Protein Regulate C-MYC Transcription: Novel Therapeutic Target for Metastatic Prostate CancerPMID 31467179Read ↗

MDC1 functionally identified as an androgen receptor co-activator participates in suppression of prostate cancerSemantic proximity Read ↗

ERK and AKT Signaling Drive MED1 Overexpression in Prostate Cancer in Association with Elevated Proliferation and TumorigenicitySemantic proximity Read ↗

MEN1 silencing aggravates tumorigenic potential of AR-independent prostate cancer cells through nuclear translocation and activation of JunD and β-cateninSemantic proximity Read ↗

BET inhibitor blocks the oncogenic function of nucleophosmin 1 in castration-resistant prostate cancer by interfering with the c-Myc signaling pathwaySemantic proximity Read ↗

MED12 overexpression is a frequent event in castration-resistant prostate cancerSemantic proximity Read ↗

MEIS-mediated suppression of human prostate cancer growth and metastasis through HOXB13-dependent regulation of proteoglycansSemantic proximity Read ↗

MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic DiseaseSemantic proximity Read ↗

CRISPR screening reveals SYCP3 as a key driver of metastasis in prostate cancerSemantic proximity Read ↗

SETD1A Promotes Proliferation of Castration-Resistant Prostate Cancer Cells via FOXM1 TranscriptionSemantic proximity Read ↗

Loss of polarity protein Par3, via transcription factor Snail, promotes bladder cancer metastasis.Semantic proximity Read ↗

SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3.Semantic proximity Read ↗

Essential Role for Activation of the Polycomb Group (PcG) Protein Chromatin Silencing Pathway in Metastatic Prostate CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.